The US Life Sciences labor market strengthened sharply in Q2 2026, with employers posting 418,095 job ads, up 15.1% from Q1 2026 and 20.7% from Q2 2025. The pace of improvement exceeded the gradual stabilization pattern seen in prior quarters and marked the strongest broad-based advance in the current cycle.

All three major sub-sectors expanded. Research, Testing and Medical Labs (RTM) increased 31.1% year over year, Pharmaceutical & Medicine Manufacturing (PMM) rose 20.8%, and Medical Devices & Equipment (MDE) increased 6.7%. On a sequential basis, PMM advanced 16.8%, MDE 15.9%, and RTM 13.2%, indicating

that the rebound extended beyond research and services into manufacturing and device-related hiring.

Hiring demand remained concentrated in execution-critical capabilities, including pharmaceuticals, marketing, project management, continuous improvement, biotechnology, medical devices, clinical trials, and auditing. Capital-market conditions also became more constructive, with stronger M&A activity, improved IPO performance among select issuers, and a substantial decline in announced workforce reductions compared with both Q1 and the prior-year quarter.

Overall, Q2 represented a meaningful shift in labor-market direction. The breadth of the increase suggests more than a temporary improvement, although capital discipline and selective hiring remain firmly in place. The next test will be whether employers sustain this higher level of demand through Q3.

View additional life sciences hiring benchmarks and market tools.